Tackling Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the Unite States.

What Is AD?

Outside-In Hypothesis External Factors Contribute to Barrier Dysfunction

Skin Barrier Dysfunction Predictive of AD

Other Factors in Barrier Dysfunction

Inside-Out Hypothesis Immune Dysregulation + Inflammation = AD

Inside-Out Hypothesis Role of Increased PDE4

Key Takeaway No. 1

Prevalence of AD in Specific Populations

Clinical Manifestations of AD

Clinical Manifestations of AD (cont) Older Children and Adults

Importance of Differential Diagnosis

Burden of AD on Children and Caregivers

Pediatric Comorbidities

Key Takeaway No. 2

Determining Severity of AD

Mild to Moderate to Severe AD

Concerns for Skin Infections

Key Takeaway No. 3

Therapeutic Goals and Care Management

Care Management: Topical Corticosteroids

Care Management: Other Pharmacotherapy

Systemic Agents to Treat Severe AD

Key Takeaway No. 4

Creating the Action Plan

Written Action Plan

Barriers to Adherence

Key Takeaway No. 5

Concluding Remarks

Abbreviations